Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Investigating the Impact of Osteoclasts on Drug Resistance in Acute Myeloid Leukemia
EF 2023-24
Résumé
The bone marrow (BM) contains hematopoietic stem cells, which give rise to all blood cells in the body. These stem cells are carefully supported by the BM microenvironment: a diverse group of cell types that provide structural support and elaborate cell signaling. One important part of this microenvironment is the balance of bone formation maintained by bone-forming osteoblast cells and bone-resorbing osteoclast (OC) cells, found in the endosteal niche of the BM. Acute myeloid leukemia (AML) is an aggressive hematological cancer for which chemotherapy resistance remains a critical challenge for patients, with about half of all patients relapsing. The association of leukemic cells with the endosteal niche is thought to be a contributing factor to the development of drug resistance. While the role of the endosteal niche in hematopoiesis has been established, the significance of OCs remains largely underexplored. In this proposal, we first aim to solidify the link between OCs and AML by establishing a co-culture system of OCs and resistance-prone AML cells, and then investigate their drug resistance to a panel of chemotherapeutic drugs. We then aim to inhibit OC function with a clinically approved bisphosphonate drug, and transplant the AML cells from aim 1 into mice that have intact and functioning BM. This will allow us to evaluate the impact of OC inhibition on the behavior of AML cells in our animal model. Finally, in our third aim we will assess any synergistic effects of OC inhibition in the same mouse model with the drug panel from our first aim. The described set of experiments will help elucidate the interplay between the BM microenvironment and AML drug resistance and pave the way towards clinically translatable strategies for overcoming AML disease relapse.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505982
Name
Djaksigulova Diana
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Impact of Osteoclasts on Drug Resistance in Acute Myeloid Leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Organoids; Osteoclasts
Abstract
The bone marrow (BM) contains hematopoietic stem cells, which give rise to all blood cells in the body. These stem cells are carefully supported by the BM microenvironment: a diverse group of cell types that provide structural support and elaborate cell signaling. One important part of this microenvironment is the balance of bone formation maintained by bone-forming osteoblast cells and bone-resorbing osteoclast (OC) cells, found in the endosteal niche of the BM. Acute myeloid leukemia (AML) is an aggressive hematological cancer for which chemotherapy resistance remains a critical challenge for patients, with about half of all patients relapsing. The association of leukemic cells with the endosteal niche is thought to be a contributing factor to the development of drug resistance. While the role of the endosteal niche in hematopoiesis has been established, the significance of OCs remains largely underexplored. In this proposal, we first aim to solidify the link between OCs and AML by establishing a co-culture system of OCs and resistance-prone AML cells, and then investigate their drug resistance to a panel of chemotherapeutic drugs. We then aim to inhibit OC function with a clinically approved bisphosphonate drug, and transplant the AML cells from aim 1 into mice that have intact and functioning BM. This will allow us to evaluate the impact of OC inhibition on the behavior of AML cells in our animal model. Finally, in our third aim we will assess any synergistic effects of OC inhibition in the same mouse model with the drug panel from our first aim. The described set of experiments will help elucidate the interplay between the BM microenvironment and AML drug resistance and pave the way towards clinically translatable strategies for overcoming AML disease relapse.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Djaksigulova, Diana
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~